Calypte Biomed,Fortsetzung teil 3
hoffentlich hast du gestern auf mich gehört und deine gewinne realisiert....
jedenfalls raus aus dem papier.
Smoky
Calypte Biomedical Submits Investigational Device Exemption Application for HIV-1 Rapid Blood Test
ALAMEDA, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, announced today that it is submitting an application with the U.S. Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) for its HIV-1 lateral flow antibody Rapid Blood Test to be performed on whole blood. This represents the Company's first application in connection with several rapid HIV diagnostic tests the Company has under development. The Company expects to submit a similar application for its urine-based HIV-1 Rapid Test sometime next year.
"This application represents an important step in our attempt to penetrate the U.S. market for our suite of Rapid Test products," said Tony Cataldo, Calypte Biomedical's Chairman. "While we believe that near-term international opportunities for our Urine-based Rapid Test (once approved/commercially viable) will drive revenue growth, ultimately we feel that the North American market will represent a potential for substantial commercial opportunity for our Urine-based Rapid Test. We believe our ability to market a blood-based Rapid Test product will raise awareness among the U.S. medical community for our suite of Rapid Test products and ultimately shorten the sales cycle for our urine-based HIV product. In addition, we anticipate that there will be opportunities to cross-sell our blood related testing products to the medical community, as it acts as an excellent confirmatory test for urine."
Under federal regulations, the FDA can authorize the use of an investigational test in the treatment of patients with serious or life-threatening conditions when no comparable or satisfactory alternative exists. The Company believes that its HIV-1 Rapid Blood Test may be cheaper than similar products currently being marketed in the U.S.
Der erster Schritt zur Genehmigung der neuen Calypte-Schnelltests (Blut und Urin) im Genehmigungs-Jungel der FDA. (erst mal nur für die Bluttests, für Urin folgt: irgendwann nächstes Jahr)
Grüße, ZN
andererseits kommt auch etwas Ruhe rein - dummerweise kam dann immer irgend so eine Mistmeldung und das wars dann wieder
jetzt beruhigt sie sich halt wieder mal
Du kannst auf und nieder springen , aber ohne fund. News ist Caly halt momentan einfach nicht mehr wert !
Außerdem bin ich noch straff investiert, und hoffe auch wieder auf bessere Zeiten , das ist nun einmal die Realität.
High: 1.230
Low: 1.110
Open: 1.190
Change: -0.02
Volume: 1,982,900
Bid: 0.890
Ask: 1.115
Bid/Ask Size: 500 / 500
52 Wk High: 1.799
52 Wk Low: 0.012
%Change: -1.8%
Market Cap: N/A
Price/Sales: N/A
EPS: $0.00
P/E Ratio: N/A
Market Data Powered By ComStock
11/06/03 - 1:05 p.m. Eastern -- No Quote Delay.
Last 10 trades
Time Price Volume Exchange Info
13:05:23 1.110 5000 OTCBB
13:05:20 1.110 700 OTCBB
13:01:47 1.120 500 OTCBB at Ask
12:59:36 1.110 10000 OTCBB
12:56:39 1.120 500 OTCBB at Ask
12:56:18 1.120 500 OTCBB at Ask
12:54:14 1.120 100 OTCBB at Ask
12:51:20 1.120 500 OTCBB
12:51:20 1.120 9000 OTCBB
12:51:20 1.110 10000 OTCBB
High: 1.230
Low: 1.105
Open: 1.190
Change: -0.03
Volume: 2,010,600
Bid: 1.100
Ask: 1.240
Bid/Ask Size: 500 / 500
52 Wk High: 1.799
52 Wk Low: 0.012
%Change: -2.3%
Market Cap: N/A
Price/Sales: N/A
EPS: $0.00
P/E Ratio: N/A
Market Data Powered By ComStock
11/06/03 - 1:16 p.m. Eastern -- No Quote Delay.
Last 10 trades
Time Price Volume Exchange Info
13:13:00 1.105 1000 OTCBB
13:12:05 1.110 1000 OTCBB
13:10:44 1.110 3000 OTCBB
13:10:40 1.110 5000 OTCBB
13:09:13 1.110 1000 OTCBB
13:09:06 1.110 2000 OTCBB
13:08:54 1.110 500 OTCBB at Ask
13:08:50 1.110 2000 OTCBB
13:08:00 1.110 500 OTCBB
13:07:57 1.110 700 OTCBB